NCT05420493View on ClinicalTrials.gov

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 6, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2025

Conditions

Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon Hodgkin Lymphoma

Interventions

BIOLOGICAL

CAR-T cells

Drug: CAR-T cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

250000

RECRUITING

Shandong Second Provincial General Hospital, Jinan

All Listed Sponsors

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY

NCT05420493 - Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter